Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 3 15
Substance-Related Disorders 44 73
Substance Abuse Problem 73

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 44 D019966
NCIt 50 C16522
SNOMED-CT 68 26416006

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to impulse control disorder and eating disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript
MIAT turned out to be one of the top twenty-five,of nearly 39,000,transcripts differentially expressed in the nucleus accumbens,a midbrain region pivotal in drug abuse,in a case-control study of human heroin and cocaine abusers.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Amphetamine and Buprenorphine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and placenta, and related phenotypes are behavior/neurological and homeostasis/metabolism

CDC : 3 Related Links

Wikipedia : 76 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 32.4 DRD2 DRD3 DRD4
2 eating disorder 32.1 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
3 cocaine abuse 32.1 DBH DRD2 PRL SLC6A3 SLC6A4
4 depression 31.2 BDNF MAOA SLC6A4
5 alcohol abuse 30.9 BDNF DRD2 DRD3 DRD4 GABRA2 PRL
6 alexithymia 30.5 COMT DRD2 SLC6A4
7 traumatic brain injury 30.5 BDNF COMT DRD2
8 movement disease 30.5 DRD2 DRD3 SLC6A3
9 generalized anxiety disorder 30.5 BDNF DRD2 MAOA SLC6A4
10 antisocial personality disorder 30.5 COMT DRD2 HTR1B MAOA SLC6A3 SLC6A4
11 brain injury 30.5 BDNF COMT DRD2
12 bipolar i disorder 30.4 BDNF COMT SLC6A4
13 tobacco addiction 30.1 COMT DRD2 MAOA SLC6A3
14 anxiety 30.1 BDNF COMT CYP2D6 MAOA NPY SLC6A4
15 borderline personality disorder 30.1 BDNF COMT HTR1B MAOA SLC6A4
16 pathological gambling 30.0 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
17 post-traumatic stress disorder 30.0 BDNF COMT DRD2 MAOA SLC6A4
18 anorexia nervosa 29.7 BDNF COMT NPY PRL SLC6A4
19 schizoaffective disorder 29.6 BDNF COMT DRD2 DRD3 PRL SLC6A4
20 personality disorder 29.6 BDNF COMT DRD2 DRD3 DRD4 HTR1B
21 gilles de la tourette syndrome 29.6 BDNF COMT DBH DRD2 DRD4 DRD5
22 conduct disorder 29.4 COMT DBH DRD2 DRD4 DRD5 MAOA
23 mood disorder 29.1 BDNF COMT DRD2 DRD3 DRD4 HTR1B
24 disease of mental health 28.7 BDNF COMT CYP2D6 DRD2 DRD3 DRD4
25 bipolar disorder 28.4 BDNF COMT DBH DRD2 DRD3 DRD4
26 autism 28.3 BDNF COMT DRD2 DRD3 DRD4 MAOA
27 substance dependence 28.2 BDNF CYP2D6 DRD2 DRD3 DRD4 DRD5
28 alcohol dependence 27.0 BDNF COMT DBH DRD2 DRD3 DRD4
29 attention deficit-hyperactivity disorder 26.5 BDNF COMT CYP2D6 DBH DRD2 DRD3
30 schizophrenia 25.4 BDNF COMT CYP2D6 DBH DRD2 DRD3
31 opioid abuse 11.2
32 cannabis abuse 11.2
33 panic disorder 1 10.9
34 antidepressant type abuse 10.9
35 hallucinogen abuse 10.9
36 phencyclidine abuse 10.9
37 amphetamine abuse 10.9
38 barbiturate abuse 10.9
39 learning disability 10.9
40 delusional disorder 10.8 DRD2 DRD3 DRD4
41 polysubstance abuse 10.7 COMT DRD2 DRD3
42 obsessive-compulsive personality disorder 10.7 DRD3 SLC6A4
43 alcohol-induced mental disorder 10.7 DRD2 SLC6A3 SLC6A4
44 alcoholic psychosis 10.7 DRD2 SLC6A3 SLC6A4
45 schizophreniform disorder 10.7 COMT DRD2 PRL
46 opiate dependence 10.7 DRD2 DRD3 SLC6A4
47 phobic disorder 10.6 COMT MAOA SLC6A4
48 phobia, specific 10.6 COMT MAOA
49 endogenous depression 10.6 BDNF MAOA SLC6A4
50 atypical depressive disorder 10.6 MAOA SLC6A4

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 HTR1B DRD2 BDNF DRD3 COMT DRD4
2 homeostasis/metabolism MP:0005376 10.16 DRD2 BDNF DRD3 COMT DRD4 CYBB
3 cardiovascular system MP:0005385 10.06 DBH DRD2 DRD3 COMT CYBB DRD5
4 growth/size/body region MP:0005378 10.06 DBH DRD2 BDNF DRD3 CYBB SLC6A3
5 endocrine/exocrine gland MP:0005379 10.02 HTR1B DRD2 BDNF COMT DRD5 DBH
6 integument MP:0010771 9.76 DRD2 BDNF DBH GABRA2 SLC6A3 SLC6A4
7 mortality/aging MP:0010768 9.73 DBH GABRA2 HTR1B DRD2 BDNF DRD3
8 nervous system MP:0003631 9.53 DRD2 BDNF DRD3 COMT DRD4 CYBB

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 300-62-9 5826 3007
2
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
3
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 93-14-1 3516
5
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
6
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
7
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 1 129722-12-9 60795
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
9
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
10
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-36-2 5760 446220
11
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
12
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
13
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
14
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
15
Disulfiram Approved Phase 4,Phase 1 97-77-8 3117
16
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
17
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 537-46-2 10836
18
Valproic Acid Approved, Investigational Phase 4,Phase 3,Not Applicable 99-66-1 3121
19
Risperidone Approved, Investigational Phase 4,Phase 2 106266-06-2 5073
20
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Lorazepam Approved Phase 4 846-49-1 3958
23
Clozapine Approved Phase 4 5786-21-0 2818
24
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
25
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 51-64-9 5826
26
Menthol Approved Phase 4,Phase 1,Not Applicable 2216-51-5 16666
27
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
28
Sofosbuvir Approved Phase 4,Phase 3 1190307-88-0 45375808
29
Ziprasidone Approved Phase 4 146939-27-7 60854
30
Allopurinol Approved Phase 4 315-30-0 2094
31
Choline Approved, Nutraceutical Phase 4,Not Applicable 62-49-7 305
32
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
33
Betadex Experimental Phase 4 7585-39-9 320761
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antitussive Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Not Applicable
42 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Atomoxetine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antimanic Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 988)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
4 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
5 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
6 Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
7 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
8 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
9 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
10 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
11 Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs Completed NCT00137306 Phase 4
12 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
13 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
14 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
15 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
16 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
17 The Whole Day First Grade Program Completed NCT00257088 Phase 4
18 Study of Aripiprazole in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
19 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
20 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
21 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
22 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
23 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
24 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
25 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
26 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
27 Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT) Completed NCT00326781 Phase 4 Nicoderm Transdermal Patch;Nicotine Nasal Spray
28 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
29 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
30 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
31 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
32 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
33 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
34 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
35 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
36 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4 SODAS MPH;Naltrexone
37 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
38 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
39 PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 Completed NCT02149888 Phase 4 Tenofovir/emtricitabine
40 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
41 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Recruiting NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
42 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
43 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
44 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units Active, not recruiting NCT01825057 Phase 4
45 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care Enrolling by invitation NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
46 Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use Not yet recruiting NCT03266445 Phase 4 buprenorphine/naloxone
47 The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Not yet recruiting NCT02935998 Phase 4 Ziprasidone
48 Telemonitoring of Uncontrolled Hypertension Not yet recruiting NCT02730052 Phase 4
49 Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
50 Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment Terminated NCT00464191 Phase 4 escitalopram

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

41
Testes, Brain, Placenta, Liver, Pituitary, Spinal Cord, Heart

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 791)
# Title Authors Year
1
Understanding child protection decisions involving parents with mental illness and substance abuse. ( 29772468 )
2018
2
Primary Hip and Knee Arthroplasty in a Safety Net Hospital: Substance Abuse and Other Factors Affecting Short-term Complications. ( 29853309 )
2018
3
Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores. ( 29974660 )
2018
4
Why Don't Hospitals Prioritize Substance Abuse in Their Community Benefit Programming? ( 29346190 )
2018
5
Interventions for Women With Substance Abuse Issues: A Scoping Review. ( 29426381 )
2018
6
Child maltreatment severity, chronic substance abuse, and disability status. ( 29878835 )
2018
7
Psychoactive substance abuse and dependence and its association with anxiety disorders: a population-based study of young adults in Brazil. ( 29451585 )
2018
8
Barriers and Facilitators to Treatment Engagement Among Clients in Inpatient Substance Abuse Treatment. ( 29683040 )
2018
9
Velopharyngeal dysfunction from intranasal substance abuse: Case series and review of literature. ( 29756302 )
2018
10
Stigma as a Barrier to Substance Abuse Treatment Among Those With Unmet Need: An Analysis of Parenthood and Marital Status. ( 29307947 )
2018
11
Successful Use of Ketamine for Burst Suppression in Super Refractory Status Epilepticus Following Substance Abuse. ( 29422735 )
2018
12
Detecting Recovery Problems Just in Time: Application of Automated Linguistic Analysis and Supervised Machine Learning to an Online Substance Abuse Forum. ( 29895517 )
2018
13
Reward-Based Learning as a Function of Severity of Substance Abuse Risk in Drug-NaA^ve Youth with ADHD. ( 29924634 )
2018
14
Victimization of the Substance Abuse and Sexual Behaviors among Junior High School Students in Cambodia. ( 29845023 )
2018
15
Substance Abuse Surveillance among Construction Workers: A Proof of Concept Alternative Approach. ( 29303868 )
2018
16
Adding Resistance Training to the Standard of Care for Inpatient Substance Abuse Treatment in Men With Human Immunodeficiency Virus Improves Skeletal Muscle Health Without Altering Cytokine Concentrations. ( 29257793 )
2018
17
Ambient air pollution exposure and emergency department visits for substance abuse. ( 29958279 )
2018
18
Gender and Cultural Adaptations for Diversity: A Systematic Review of Alcohol and Substance Abuse Interventions for Latino Males. ( 29364763 )
2018
19
Redeveloping Substance Abuse Treatment for Military Personnel. ( 29779198 )
2018
20
Characteristics of Substance Abuse and Self-Injury among American Indian Adolescents Who Have Engaged in Binge Drinking. ( 29889946 )
2018
21
Perceptions of child protective services among pregnant or recently pregnant, opioid-using women in substance abuse treatment. ( 29433069 )
2018
22
Tobacco Cessation Interventions and Smoke-Free Policies in Mental Health and Substance Abuse Treatment Facilities - United States, 2016. ( 29746451 )
2018
23
Civil commitment laws for substance abuse treatment: An acceptable option? ( 29857597 )
2018
24
Web-Based Intervention to Reduce Substance Abuse and Depression: A Three Arm Randomized Trial in Mexico. ( 29768070 )
2018
25
Long-Term Implications Of A Short-Term Policy: Redacting Substance Abuse Data. ( 29863917 )
2018
26
The Untreated Addiction: Going Tobacco-Free in a VA Substance Abuse Residential Rehabilitation Treatment Program (SARRTP). ( 29721729 )
2018
27
Patterns of Substance Abuse in Offenders With Schizophrenia- Illness-Related or Criminal Life-Style? ( 29946271 )
2018
28
Cervical dystonia and substance abuse. ( 29569175 )
2018
29
Pulmonary Alveolar Proteinosis in Setting of Inhaled Toxin Exposure and Chronic Substance Abuse. ( 29607238 )
2018
30
Cultural and Social Predictors of Substance Abuse Recovery among American Indian and Non-American Indian Pregnant and Parenting Women. ( 29932824 )
2018
31
Intravenous Valproic Acid Add-On Therapy in Acute Agitation Adolescents With Suspected Substance Abuse: A Report of Six Cases. ( 29303801 )
2018
32
A Shared Decision-Making Tool to Prevent Substance Abuse: Protocol for a Randomized Controlled Trial. ( 29326094 )
2018
33
Burden of Schizophrenia or Psychosis-Related Symptoms in Adults Undergoing Substance Abuse Evaluation. ( 29905667 )
2018
34
The case for considering rather than ignoring race/ethnicity in substance abuse research. ( 29388881 )
2018
35
Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. ( 29360053 )
2018
36
Gender Differences in Complex Posttraumatic Stress Symptoms, and Their Relationship to Mental Health and Substance Abuse Outcomes in Incarcerated Adults. ( 29294660 )
2017
37
Assessing the Mental Health, Substance Abuse, Cognitive Functioning, and Social/Emotional Well-Being Needs of Aboriginal Prisoners in Australia. ( 28823188 )
2017
38
Failure to get into substance abuse treatment. ( 28017185 )
2017
39
Childhood Maltreatment and Unprotected Sex among Female Juvenile Offenders: Evidence of Mediation by Substance Abuse and Psychological Distress. ( 28087129 )
2017
40
Current status and future prospects for the development of substance abuse vaccines. ( 28918668 )
2017
41
Family and Peer-Group Substance Abuse as a Risk-Factor for Opioid Misuse Behaviors for a Young Adult with Cancer-Related Pain-A Case Study. ( 28910174 )
2017
42
Tinnitus, Anxiety, Depression and Substance Abuse in Rock Musicians a Norwegian Survey. ( 28723602 )
2017
43
Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse. ( 28809856 )
2017
44
"Keeping It Real": The Relational Effects of Trauma Among African American Women and Their Substance Abuse Treatment Counselors. ( 29294757 )
2017
45
Mental Health, Substance Abuse, and Suicide Among Homeless Adults. ( 28678621 )
2017
46
Offenders With Substance Abuse Who Receive Mandatory Psychiatric Treatment. ( 28939729 )
2017
47
Opioids and Substance Abuse: Education or Just Regulation? ( 28755098 )
2017
48
Are There Tools to Screen Children and Adolescents in the Emergency Department With Mental Health and Substance Abuse Issues? ( 28935284 )
2017
49
Rescuing Israeli travellers: effects of substance abuse, mental health, geographic region of rescue, gender and age of rescuees. ( 28931135 )
2017
50
Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. ( 28166863 )
2017

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 DRD2 DRD3 DRD4 DRD5 GABRA2 HTR1B
2
Show member pathways
12.85 COMT DRD2 DRD3 DRD4 DRD5 MAOA
3
Show member pathways
12.65 BDNF DRD2 DRD3 DRD4 DRD5
4 12.18 DRD2 DRD3 DRD4 DRD5
6
Show member pathways
12.02 BDNF DRD2 DRD5 HTR1B NPY
7 11.87 BDNF MAOA PLP1 SLC6A4 TF
8
Show member pathways
11.86 BDNF DRD2 MAOA SLC6A3
9 11.83 CYP2D6 HTR1B MAOA SLC6A4
10
Show member pathways
11.78 DRD2 DRD3 DRD4
11 11.71 DBH MAOA TDO2
12
Show member pathways
11.62 COMT CYP2D6 SLC6A4
13
Show member pathways
11.61 DRD2 DRD3 DRD4 DRD5 HTR1B
14
Show member pathways
11.59 COMT DBH MAOA
15 11.08 HTR1B MAOA SLC6A4
16
Show member pathways
10.92 COMT DBH MAOA
17 10.89 DRD2 DRD3 DRD5
18
Show member pathways
10.77 COMT MAOA
19 10.73 COMT MAOA
20
Show member pathways
10.67 COMT MAOA SLC6A3 SLC6A4
21
Show member pathways
10.65 DBH MAOA SLC6A3 SLC6A4 TDO2

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.61 CYBB DRD2 DRD3 DRD4 DRD5 GABRA2
2 axon GO:0030424 9.55 BDNF COMT DRD2 GABRA2 SLC6A3
3 endocytic vesicle GO:0030139 9.5 DRD2 DRD3 TF
4 dendrite GO:0030425 9.1 BDNF COMT CYBB DRD2 GABRA2 HTR1B
5 integral component of membrane GO:0016021 10.1 COMT CYBB CYP2D6 DBH DRD2 DRD3

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 COMT CYBB DRD2 DRD3 HTR1B SLC6A3
2 chemical synaptic transmission GO:0007268 9.91 DBH DRD5 GABRA2 HTR1B NPY PLP1
3 response to ethanol GO:0045471 9.9 DRD2 DRD3 HTR1B SLC6A3
4 cellular calcium ion homeostasis GO:0006874 9.87 DRD3 DRD4 DRD5
5 locomotory behavior GO:0007626 9.87 DBH DRD2 DRD3 SLC6A3
6 memory GO:0007613 9.85 BDNF DBH SLC6A4
7 learning GO:0007612 9.83 COMT DRD3 DRD5
8 social behavior GO:0035176 9.83 DRD3 DRD4 SLC6A4
9 visual learning GO:0008542 9.82 DBH DRD2 DRD3
10 neurotransmitter transport GO:0006836 9.81 GABRA2 SLC6A3 SLC6A4
11 feeding behavior GO:0007631 9.81 DRD2 HTR1B NPY
12 associative learning GO:0008306 9.78 DBH DRD2 DRD5
13 negative regulation of blood pressure GO:0045776 9.77 DRD2 DRD3 DRD5
14 arachidonic acid secretion GO:0050482 9.75 DRD2 DRD3 DRD4
15 behavioral response to cocaine GO:0048148 9.73 DRD2 DRD3 DRD4
16 regulation of dopamine secretion GO:0014059 9.72 DRD2 DRD3 HTR1B
17 response to pain GO:0048265 9.71 COMT DBH
18 synaptic transmission, dopaminergic GO:0001963 9.71 DRD2 DRD3 DRD5
19 response to iron ion GO:0010039 9.7 DRD2 SLC6A3
20 vasoconstriction GO:0042310 9.7 HTR1B SLC6A4
21 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD2 HTR1B
22 negative regulation of protein secretion GO:0050709 9.7 DRD2 DRD3 DRD4
23 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
24 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A3 SLC6A4
25 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.69 DRD2 DRD5
26 behavioral response to ethanol GO:0048149 9.69 DBH DRD2 DRD4
27 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD2 DRD4
28 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
29 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
30 regulation of dopamine metabolic process GO:0042053 9.68 DRD4 SLC6A3
31 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD3 DRD5
32 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
33 prepulse inhibition GO:0060134 9.67 DRD2 DRD3 SLC6A3
34 dopamine receptor signaling pathway GO:0007212 9.67 DRD2 DRD3 DRD4 DRD5
35 adenohypophysis development GO:0021984 9.66 DRD2 SLC6A3
36 dopamine uptake involved in synaptic transmission GO:0051583 9.65 SLC6A3 SLC6A4
37 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD2 DRD3
38 G-protein coupled receptor internalization GO:0002031 9.65 DRD2 DRD3 HTR1B
39 acid secretion GO:0046717 9.63 DRD2 DRD3
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.63 DRD2 DRD3 DRD4
41 fear response GO:0042596 9.62 DBH DRD4
42 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD2 DRD4
43 negative regulation of dopamine receptor signaling pathway GO:0060160 9.61 DRD2 DRD3
44 regulation of locomotion involved in locomotory behavior GO:0090325 9.58 DRD2 DRD3
45 dopamine metabolic process GO:0042417 9.56 COMT DRD2 DRD3 DRD4
46 response to cocaine GO:0042220 9.55 DRD2 DRD3 DRD5 HTR1B SLC6A3
47 response to histamine GO:0034776 9.5 DRD2 DRD3 DRD4
48 dopamine catabolic process GO:0042420 9.26 COMT DBH MAOA SLC6A3
49 response to amphetamine GO:0001975 9.02 DBH DRD2 DRD3 DRD4 DRD5

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.91 DRD2 DRD3 DRD4 DRD5 HTR1B NPY
2 oxidoreductase activity GO:0016491 9.85 CYBB CYP2D6 DBH MAOA TDO2
3 obsolete signal transducer activity GO:0004871 9.77 DRD2 DRD3 DRD4 DRD5 HTR1B
4 drug binding GO:0008144 9.63 CYP2D6 DRD2 DRD3 DRD4 HTR1B SLC6A3
5 neurotransmitter:sodium symporter activity GO:0005328 9.48 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3 DRD4 DRD5
10 dopamine binding GO:0035240 9.02 DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources for Substance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....